Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) is dated November 1, 2019. The report addresses Item 8.01 (Other Events) regarding the extension of expiration dates for specific debt exchange offers and consent solicitations related to the company's planned acquisition of Celgene Corporation.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only financial figure disclosed relates to the aggregate principal amount of notes involved in the exchange offer:
- Celgene Notes Exchange Amount: Up to $19,850,000,000.
Material Changes
The primary material change reported is the extension of the expiration date for the Exchange Offers and Consent Solicitations:
- Previous Expiration Date: November 4, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: November 6, 2019, at 5:00 p.m. New York City time.
- Purpose: To allow additional time for holders of Celgene Notes to exchange them for new Bristol-Myers Squibb notes and cash, and to solicit consents to amend restrictive covenants in the Celgene Notes indentures.
Outlook, Risks, and Management Commentary
Merger Timeline: The closing of the Celgene Merger is expected to occur by the end of 2019. The settlement of the Exchange Offers is expected to occur promptly after the Expiration Date and on or about the Merger closing date.
Conditions: The Exchange Offers and Consent Solicitations are strictly conditioned upon the closing of the Merger, a condition that cannot be waived by Bristol-Myers Squibb.
Future Extensions: Management noted that the Expiration Date may be further extended one or more times if necessary, with advance notice provided to holders.
Amendments: Supplemental indentures to eliminate restrictive covenants were executed on May 1, 2019, but will only become operative upon the settlement of the Exchange Offers.
Investor Verification Checklist
- Verify the final closing date of the Celgene Merger to confirm if it occurs by the end of 2019 as expected.
- Monitor for further press releases regarding additional extensions of the Exchange Offer expiration date beyond November 6, 2019.
- Confirm the final settlement date of the Exchange Offers to determine when the new notes and cash will be issued.
- Review the attached press release (Exhibit 99.1) for detailed terms of the exchange and consent solicitation.